Pristiq
Mar 14, 2017
Pfizer faces patent loss; Allergan over generics probe; Sun Pharma rallies
Pfizer faces first 2017 patent loss as Pristiq generics arrive Pfizer faces a challenging year on the patent loss front, starting with the generics of its antidepressant Pristiq now hitting the market. Mylan today said it had launched its copycat of desvenlafaxine extended-release tablets, in 50 mg and 100 mg doses....
Read More...
-Agonist.png "Toll-like Receptors Agonist")
